Zydus Cadila has received final USFDA approval to market generic Lansoprazole delayed release orally disintegrating tablets in the strengths of 15 mg and 30 mg. Lansoprazole tablets are used for the treatment of conditions such as ulcers, gastroesophageal reflux disease (GERD) and Zollinger-Ellison syndrome that are caused by stomach acid.
The drug is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The company is likely to produce the drug at its manufacturing facility in Moraya near Ahmedabad in Gujarat.
Company Profile : Cadila Healthcare Ltd
Leave a Reply